The purpose of this study is to learn about:
how Zavegepant is changed and removed from the body after taken.
safety of Zavegepant.
the extent to which side effects can be tolerated after taking Zavegepant for the possible short-term treatment of migraine.
This study is seeking participants who:
are healthy Chinese adults and includes participants who are between 18 to 55 years old.
have body mass index (BMI) of 18 to 30 kg/m^2.
have a total body weight of:
equal to or more than 50 kilograms (110 pounds) for males.
equal to or more than 45 kilograms (99 pounds) for females.
are non-smoker (no use of tobacco or nicotine products).
All participants in this study will receive Zavegepant by nose, once at the study clinic.
The experiences of the participants receiving the study medicine will be looked at. This will help see if the study medicine is safe.
Participants will take part in this study for around 9 weeks. During this time, participants will have 2 study visits at the study clinic and 1 contact over the phone.
Closest Location
NCT# stands for National Clinical Trial number. This is a unique identification code given to each clinical trial registered on ClinicalTrials.gov. The format is "NCT" followed by an 8-digit number (for example, NCT00000419). Also called the ClinicalTrials.gov identifier.
Each clinical study has its own guidelines for who may participate, called eligibility criteria. These factors can include your age, sex, overall health, type and stage of disease, and personal treatment history. However, only the research study staff can determine if you qualify to enroll in the study.
Condition
Healthy
Sex
Male or Female
Age
18 - 55 years